Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy

• Status: Unknown status
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Accumulated clinical and experimental data suggest that dysfunctional coronary microcirculation plays a pivotal role in the progression of heart failure despite an optimal therapy used. Therefore, we hypothesize that improvement in microvascular function by calcium antagonist, verapamil may result in additional clinical benefit. Thus, the aim of this study is to compare the effect of treatment with verapamil or carvedilol on long-term outcomes in stable, chronic heart failure secondary to non-ischemic cardiomyopathy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Silesia
• Treatments: Carvedilol; Verapamil

Criteria

Inclusion Criteria:

• Chronic heart failure (NYHA II and III; LV ejection fraction, ≤ 35%) secondary to non-ischemic cardiomyopathy. Stable condition at least 6 months before enrollment on conventional therapy (beta-blockers, ACE inhibitors and diuretics).

Exclusion Criteria:

• improvement in clinical status on conventional therapy in out-patients period preceded hospitalization

• any changes narrowing epicardial coronary arteries in coronary angiography,

• insulin dependent diabetes,

• valvular heart disease (except the relative mitral regurgitation),

• endocrine disease,

• lack of written informed consent,

• significant renal and liver diseases,

• drug or alcohol abuse,

• therapy with steroids or calcium blockers within 3 months before screening